vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and Colgate-Palmolive (CL). Click either name above to swap in a different company.
Colgate-Palmolive is the larger business by last-quarter revenue ($5.2B vs $8.1M, roughly 642.9× Axil Brands, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -0.7%, a 9.4% gap on every dollar of revenue. On growth, Colgate-Palmolive posted the faster year-over-year revenue change (5.8% vs 5.2%). Colgate-Palmolive produced more free cash flow last quarter ($1.3B vs $906.4K). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs 1.6%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
The Colgate-Palmolive Company, commonly known as Colgate-Palmolive, is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. The company specializes in the production, distribution, and provision of household, health care, personal care, and veterinary products.
AXIL vs CL — Head-to-Head
Income Statement — Q2 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $5.2B |
| Net Profit | $704.9K | $-36.0M |
| Gross Margin | 68.1% | 60.2% |
| Operating Margin | 11.1% | 1.7% |
| Net Margin | 8.7% | -0.7% |
| Revenue YoY | 5.2% | 5.8% |
| Net Profit YoY | 11.2% | -104.9% |
| EPS (diluted) | $0.09 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | $5.2B | ||
| Q3 25 | $6.9M | $5.1B | ||
| Q2 25 | $5.8M | $5.1B | ||
| Q1 25 | $6.9M | $4.9B | ||
| Q4 24 | $7.7M | $4.9B | ||
| Q3 24 | $5.9M | $5.0B | ||
| Q2 24 | $6.5M | $5.1B | ||
| Q1 24 | $6.5M | $5.1B |
| Q4 25 | $704.9K | $-36.0M | ||
| Q3 25 | $334.3K | $735.0M | ||
| Q2 25 | $-245.6K | $743.0M | ||
| Q1 25 | $576.7K | $690.0M | ||
| Q4 24 | $633.7K | $738.0M | ||
| Q3 24 | $-109.8K | $737.0M | ||
| Q2 24 | $49.5K | $731.0M | ||
| Q1 24 | $781.1K | $683.0M |
| Q4 25 | 68.1% | 60.2% | ||
| Q3 25 | 67.6% | 59.4% | ||
| Q2 25 | 70.0% | 60.1% | ||
| Q1 25 | 71.7% | 60.8% | ||
| Q4 24 | 71.1% | 60.3% | ||
| Q3 24 | 71.0% | 61.1% | ||
| Q2 24 | 71.5% | 60.6% | ||
| Q1 24 | 71.5% | 60.0% |
| Q4 25 | 11.1% | 1.7% | ||
| Q3 25 | 6.0% | 20.6% | ||
| Q2 25 | 0.8% | 21.1% | ||
| Q1 25 | 8.4% | 21.9% | ||
| Q4 24 | 8.7% | 21.5% | ||
| Q3 24 | -2.4% | 21.2% | ||
| Q2 24 | 2.6% | 21.6% | ||
| Q1 24 | -1.6% | 20.7% |
| Q4 25 | 8.7% | -0.7% | ||
| Q3 25 | 4.9% | 14.3% | ||
| Q2 25 | -4.3% | 14.5% | ||
| Q1 25 | 8.3% | 14.1% | ||
| Q4 24 | 8.2% | 14.9% | ||
| Q3 24 | -1.9% | 14.6% | ||
| Q2 24 | 0.8% | 14.5% | ||
| Q1 24 | 12.1% | 13.5% |
| Q4 25 | $0.09 | $-0.04 | ||
| Q3 25 | $0.04 | $0.91 | ||
| Q2 25 | $-0.03 | $0.91 | ||
| Q1 25 | $0.07 | $0.85 | ||
| Q4 24 | $0.08 | $0.89 | ||
| Q3 24 | $-0.02 | $0.90 | ||
| Q2 24 | $0.11 | $0.89 | ||
| Q1 24 | $0.04 | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $1.4B |
| Total DebtLower is stronger | $138.3K | $7.8B |
| Stockholders' EquityBook value | $11.1M | $54.0M |
| Total Assets | $16.2M | $16.3B |
| Debt / EquityLower = less leverage | 0.01× | 145.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $1.4B | ||
| Q3 25 | $4.1M | $1.3B | ||
| Q2 25 | $4.8M | $1.2B | ||
| Q1 25 | $4.7M | $1.1B | ||
| Q4 24 | $5.2M | $1.3B | ||
| Q3 24 | $4.1M | $1.2B | ||
| Q2 24 | $3.3M | $1.1B | ||
| Q1 24 | $4.9M | $1.1B |
| Q4 25 | $138.3K | $7.8B | ||
| Q3 25 | $139.2K | — | ||
| Q2 25 | $140.2K | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $143.3K | $7.0B | ||
| Q3 24 | $144.3K | — | ||
| Q2 24 | $146.6K | — | ||
| Q1 24 | — | — |
| Q4 25 | $11.1M | $54.0M | ||
| Q3 25 | $10.2M | $856.0M | ||
| Q2 25 | $9.7M | $702.0M | ||
| Q1 25 | $9.7M | $363.0M | ||
| Q4 24 | $8.8M | $212.0M | ||
| Q3 24 | $7.9M | $435.0M | ||
| Q2 24 | $7.7M | $123.0M | ||
| Q1 24 | $8.8M | $230.0M |
| Q4 25 | $16.2M | $16.3B | ||
| Q3 25 | $15.4M | $17.5B | ||
| Q2 25 | $12.9M | $17.5B | ||
| Q1 25 | $13.0M | $16.6B | ||
| Q4 24 | $13.7M | $16.0B | ||
| Q3 24 | $11.4M | $16.8B | ||
| Q2 24 | $11.0M | $16.5B | ||
| Q1 24 | $12.7M | $16.6B |
| Q4 25 | 0.01× | 145.17× | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | 33.04× | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $1.5B |
| Free Cash FlowOCF − Capex | $906.4K | $1.3B |
| FCF MarginFCF / Revenue | 11.1% | 24.4% |
| Capex IntensityCapex / Revenue | 0.3% | 3.4% |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.6B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | $1.5B | ||
| Q3 25 | $-739.2K | $1.3B | ||
| Q2 25 | $194.4K | $884.0M | ||
| Q1 25 | $-169.9K | $600.0M | ||
| Q4 24 | $1.0M | $1.3B | ||
| Q3 24 | $897.3K | $1.2B | ||
| Q2 24 | $-336.6K | $990.0M | ||
| Q1 24 | $-912.8K | $681.0M |
| Q4 25 | $906.4K | $1.3B | ||
| Q3 25 | $-747.6K | $1.1B | ||
| Q2 25 | — | $776.0M | ||
| Q1 25 | $-258.2K | $476.0M | ||
| Q4 24 | $941.1K | $1.1B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | $-394.9K | $873.0M | ||
| Q1 24 | $-922.1K | $555.0M |
| Q4 25 | 11.1% | 24.4% | ||
| Q3 25 | -10.9% | 21.6% | ||
| Q2 25 | — | 15.2% | ||
| Q1 25 | -3.7% | 9.7% | ||
| Q4 24 | 12.2% | 21.9% | ||
| Q3 24 | — | 20.5% | ||
| Q2 24 | -6.1% | 17.3% | ||
| Q1 24 | -14.3% | 11.0% |
| Q4 25 | 0.3% | 3.4% | ||
| Q3 25 | 0.1% | 3.0% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | 1.3% | 2.5% | ||
| Q4 24 | 0.9% | 3.7% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | 0.9% | 2.3% | ||
| Q1 24 | 0.1% | 2.5% |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | 1.72× | ||
| Q2 25 | — | 1.19× | ||
| Q1 25 | -0.29× | 0.87× | ||
| Q4 24 | 1.59× | 1.72× | ||
| Q3 24 | — | 1.58× | ||
| Q2 24 | -6.80× | 1.35× | ||
| Q1 24 | -1.17× | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
Segment breakdown not available.
CL
| Other | $3.0B | 58% |
| Pet Nutrition | $1.2B | 23% |
| Oral Personal And Home Care | $1.0B | 20% |
